| http://www.w3.org/ns/prov#value | - These include mutations that constitutively activate receptor tyrosine kinases, such as FLT3 or C-KIT receptor tyrosine kinase (C-KIT), oncogenic mutations in RAS, or activating mutations in protein tyrosine phosphatases such as PTPN11 (SHP2).
|
